Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Affiliations

• ¹ Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2.
• ² Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
• ³ Boehringer Ingelheim Canada, Burlington, ON, Canada.
• ⁴ Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
• ⁵ Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.
• ⁶ Boehringer Ingelheim Norway KS, Asker, Norway.
• ⁷ Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2. david.cherney@uhn.on.ca.